Abstract
The use of a short-interval dosing schedule of hepatitis B vaccine was evaluated in 29 preterm infants born to seronegative mothers. A DNA-recombinant vaccine containing 20 μg of hepatitis B surface (HBs) antigen was administered at birth and at 15 and 45 days after birth. At the end of the vaccination schedule, seroconversion was obtained in 28 (95.4%) of the 29 infants, with a mean anti-HBs titer of 479 IU/L. The vaccine was well tolerated. These results indicate that successful immunization against hepatitis B can be achieved with a short-interval vaccination schedule in low-weight, preterm newborns.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
